GPT Rosalind: AI Architecting the Future of Drug Discovery

We explore OpenAI's April 2026 release of GPT Rosalind, a life-sciences‑focused AI that links genomics, protein structures, and metabolic pathways via a Codex plugin to accelerate discovery. The system performs multi-omics in parallel, handles end-to-end DNA design on LabBench2, and even surpasses many human experts on RNA sequence prediction. We discuss real-world deployments with Amgen, Moderna, and Los Alamos, the human-in-the-loop model, and the regulatory horizon as medicine enters an era of AI-augmented abundance.

Note:  This podcast was AI-generated, and sometimes AI can make mistakes.  Please double-check any critical information.

Sponsored by Embersilk LLC